期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 53, 期 14, 页码 5197-5212出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm100217a
关键词
-
资金
- NIH [1R01CA 149095, 1RO1CA98454, 1RO1CA51085]
- Samuel Waxman Cancer Research Foundation
- Susan B. K omen for the Cure Foundation
- Progen Pharmaceuticals, Ltd., Brisbane, Queensland, Australia
The recently discovered enzyme lysine-specific demethylase 1 (LSD1) plays an important role in the epigenetic control of gene expression, and aberrant gene silencing secondary to LSD1 overexpression is thought to contribute to the development of cancer. We recently reported a series of (bis)guanidines and (bis)biguanides that are potent inhibitors of LSD1 and induce the re-expression of aberrantly silenced tumor suppressor genes in tumor cells in vitro. We now report a series of isosteric ureas and thioureas that are also potent inhibitors of LSD1. These compounds induce increases in methylation at the histone 3 lysine 4 (H3K4) chromatin mark, a specific target of LSD1, in Calu-6 lung carcinoma cells. In addition, these analogues increase cellular levels of secreted frizzle-related protein (SFRP) 2 and.transcription factor GATA4. These compounds represent an important new series of epigenetic modulators with the potential for use as antitumor agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据